-
2024-511325-67-00
5
Chronic kidney disease
-
2024-514794-22-01
4
Eosinophilic granulomatosis with polyangiitis (EGPA)
-
2024-515287-31-00
5
Giant Cell Arteritis
-
2024-515462-14-00
6
Long term potential effect of repeated exposure to either a linear or
-
2024-515555-38-01
4
NON SMALL CELL LUNG CANCER
-
2024-516864-27-00
4
Cardiac arrest
-
2024-517796-21-00
5
Prevention of recurrence after a first episode of Venous Thromboemboli
-
2024-517861-18-00
5
Idiopathic IgA nephropathy (IgAN)
-
2024-518026-32-00
5
Invasive Breast Cancer
-
2024-518386-95-02
4
Non small-cell lung cancer
-
2024-518388-37-00
4
Intermediate risk prostate cancer
-
2024-518617-25-00
4
newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
-
2024-519087-41-00
5
Breast cancer is the most common form of cancer among women in North A
-
2024-519519-32-00
4
urothelial cancer
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2024-520081-65-00
4
NSCLC non-small cell lung cancer
-
2024-520093-34-00
5
Acinar cell prostatic carcinoma
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521666-10-01
4
Mantle Cell Lymphoma
-
2025-521827-61-00
4
refractory/relapsed multiple myeloma
-
2025-522084-15-00
10
metastatic NSCLC patients
-
2025-523389-26-00
5
Relapsed/refractory primary central nervous system lymphoma
-
2025-523579-47-00
4
moderate to severe rheumatoid arthritis (RA)